[Cytokines, endothelial dysfunction, and insulin resistance]. 2006

Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
Laboratório de Hipertensão e Diabetes, Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São PauloSão Paulo, SP. mhcarvalho@icb.usp.br

Endothelial dysfunction is associated with several vascular conditions as atherosclerosis, hypertension, hyperlipidemia and diabetes mellitus. In all these conditions insulin resistance (IR) is present. Cytokines are low molecular weight proteins with several endocrine and metabolic functions that participate of inflammation and immune response. Several of these cytokines are independent risk factors for cerebrovascular and coronary artery disease. The major sources of cytokines (adipokines) are the visceral and subcutaneous adipose tissues. Thus, increased adipose tissue mass is associated with alteration in adipokine production as over expression of tumor necrosis factor alpha, interleukin 6, plasminogen activator inhibitor 1, and under expression of adiponectin in adipocite tissue. The pro-inflammatory status associated with these changes provides a potential link between IR and endothelial dysfunction, the early stage in the atherosclerotic process, in obese individuals, and type 2 diabetic patients. Reduction of adipose tissue mass through weight reduction in association with exercise reduces TNF-alpha, IL-6, and PAI-1, increases adiponectin, and is associated with improved insulin sensitivity and endothelial function. This review will focus on the evidence for regulation of endothelial function by insulin and the adypokines such as adyponectin, leptin, resistin, IL-6 and TNF-alpha. Interaction between insulin signaling and adypokines will be discussed, as well as the concept that aberrant adypokine secretion in IR and/or obesity impairs endothelial function and contributes further to reduce insulin sensitivity.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D052242 Adiponectin A 30-kDa COMPLEMENT C1Q-related protein, the most abundant gene product secreted by FAT CELLS of the white ADIPOSE TISSUE. Adiponectin modulates several physiological processes, such as metabolism of GLUCOSE and FATTY ACIDS, and immune responses. Decreased plasma adiponectin levels are associated with INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS; OBESITY; and ATHEROSCLEROSIS. ACRP30 Protein,Adipocyte Complement-Related Protein 30-kDa,Adipocyte, C1q and Collagen Domain Containing Protein,Adipose Most Abundant Gene Transcript 1,apM-1 Protein,Adipocyte Complement Related Protein 30 kDa,apM 1 Protein
D020738 Leptin A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage. Ob Protein,Obese Protein,Ob Gene Product,Obese Gene Product,Gene Product, Ob,Gene Product, Obese

Related Publications

Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
September 2003, Best practice & research. Clinical endocrinology & metabolism,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
June 2004, Metabolic syndrome and related disorders,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
July 1994, Current opinion in nephrology and hypertension,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
May 2014, Current vascular pharmacology,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
March 2010, Biochimica et biophysica acta,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
January 2007, Journal of nephrology,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
July 1996, Diabetes research and clinical practice,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
March 2013, Reviews in endocrine & metabolic disorders,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
August 2003, The American journal of cardiology,
Maria Helena C de Carvalho, and André Luiz Colaço, and Zuleica Bruno Fortes
September 2008, Endocrinology and metabolism clinics of North America,
Copied contents to your clipboard!